Approximately two-thirds of human breast cancers are steroid hormone receptor (ER/PR) positive and treated with combinations of selective estrogen receptor modulators, gonadotropin-releasing hormone agonists, and/or aromatase inhibitors (131–133), either alone or in combination with third-generation cytotoxic or biological therapies (134, 135). Here, ESR1 is linked to breast carcinoma.